Welcome to our dedicated page for Quantum BioPharma news (Ticker: QNTM), a resource for investors and traders seeking the latest updates and insights on Quantum BioPharma stock.
Quantum BioPharma Ltd (QNTM) is a biopharmaceutical innovator developing therapies for neurodegenerative, neuropsychiatric, and inflammatory disorders. This page aggregates official news and press releases about the company’s clinical advancements, strategic investments, and market-related developments.
Investors and industry observers will find timely updates on clinical trial progress, regulatory milestones, and strategic financial decisions, including partnerships or legal initiatives impacting shareholder value. The curated content spans research breakthroughs, intellectual property updates, and balanced coverage of both pharmaceutical R&D and complementary investment activities.
All content is sourced directly from company communications to ensure accuracy. Visitors can expect coverage of FDA trial phases, compound licensing deals, and portfolio management decisions from Quantum BioPharma’s dual operational segments. Bookmark this page for efficient tracking of material events affecting QNTM’s trajectory in the biotech sector.
Quantum BioPharma (NASDAQ: QNTM) has announced the appointment of Terry Lynch to its Board of Directors, replacing Dr. Sanjiv Chopra who will continue as an advisor. Lynch, known for founding Save Canadian Mining, brings extensive experience in fighting stock market manipulation and naked short selling.
Lynch currently serves as CEO of Power Metallic Mines, which recently secured a $50 million financing. He is also a co-founder of Cardiol Therapeutics and consultant to bionxt solutions. The company has granted Lynch 50,000 stock options at C$9.90 per Class B Share, expiring March 26, 2027.
Quantum BioPharma (NASDAQ: QNTM) announced that its licensee Celly Nutrition has launched new unbuzzd™ On-the-Go Powder Stick Packs in 8-pack display boxes for U.S. retail distribution. unbuzzd™ is a beverage designed to accelerate alcohol metabolism, restore mental clarity, and reduce hangover symptoms.
The new format features TSA-compliant, pocket-sized powder sticks available in 3-pack, 8-pack, and 18-pack options, targeting convenience, liquor, and drug stores. The product is available on amazon.com and unbuzzd.com. Quantum BioPharma owns 25.71% of Celly Nutrition and receives a 7% royalty on unbuzzd™ sales until reaching $250 million, after which it drops to 3% perpetually.
The company retains full rights to develop similar products for pharmaceutical and medical uses. The launch targets the estimated $2.1 billion global hangover cure products market, supported by recent clinical trials proving the product's effectiveness in reducing blood alcohol concentration.
Quantum BioPharma (NASDAQ: QNTM) has expanded its cryptocurrency portfolio with an additional USD $1,500,000 investment in Bitcoin (BTC) and other cryptocurrencies, following Board approval. This strategic move brings the company's total crypto investment to USD $3,500,000.
The company will continue accepting future financings and transactions in cryptocurrency, viewing it as a potential hedge against the dollar and an opportunity for shareholder returns. All crypto assets are held with a compliant custodian, and transactions adhere to financial and audit regulations. Quantum BioPharma maintains flexibility to adjust its cryptocurrency holdings based on market conditions.
Quantum BioPharma (NASDAQ: QNTM) has successfully completed its Phase 1 Multiple Ascending Dose clinical trial for Lucid-21-302 (Lucid-MS), a novel multiple sclerosis drug. The Safety Review Committee confirmed the drug was well-tolerated with no safety concerns or serious adverse events reported.
Lucid-MS is a first-in-class, non-immunomodulatory, neuroprotective compound featuring a unique mechanism of action. Preclinical models demonstrated its ability to stabilize the myelin sheath surrounding nerve fibers, potentially protecting against demyelination - a key characteristic of MS that leads to progressive disability.
Following this milestone, the company is preparing to advance to Phase 2 trials in MS patients, moving closer to their goals of drug approval and commercialization.
Quantum BioPharma (NASDAQ: QNTM) has expanded its cryptocurrency holdings with an additional USD $1,000,000 investment in Bitcoin (BTC) and other cryptocurrencies, bringing its total crypto investment to USD $2,000,000. The investment, approved by the Board of Directors, is part of the company's strategic efforts to hedge against the Canadian dollar and potentially provide returns for shareholders.
The company has established infrastructure to accept cryptocurrency for financing and other transactions, with all digital assets being held by a fully compliant custodian. Quantum BioPharma emphasizes its commitment to maintaining compliance with financial and audit regulations while reserving the right to adjust its cryptocurrency holdings based on market conditions.
Quantum BioPharma (NASDAQ: QNTM) has engaged MZ Group to lead its strategic investor relations and financial communications program. MZ will develop and implement a comprehensive capital markets strategy to increase the company's visibility in the investment community.
The company is developing products focused on brain disorders and alcohol health, including unbuzzd™ and rekvry™, which address excessive alcohol use - a problem costing the U.S. approximately $249 billion annually. Additionally, Quantum is working on a potential first-in-class treatment for demyelinating diseases, including Multiple Sclerosis, which affects nearly 1 million people in the U.S. and 2.8 million worldwide.
The MZ engagement involves a two-month initial period at $10,000 per month, with automatic monthly renewals thereafter. The agreement can be terminated by either party with fifteen days' notice.
Quantum BioPharma (NASDAQ: QNTM) has announced the engagement of two agencies to enhance its public relations and investor awareness programs. Enterprise Canada has been retained indefinitely from December 18, 2024, with a structured payment plan including C$10,000 for Phase 1, C$2,500 upon completion, and C$5,000 monthly retainer for Phase 3. They will develop the company's narrative and media relations strategy.
Empire Market Ventures has been engaged for three months from February 7, 2025, for US$25,000, to provide investor awareness services including access to exclusive mailing lists and content creation.
The company highlighted its key products: unbuzzd™, a rapid alcohol detoxification beverage; rekvry™ for alcohol misuse treatment in healthcare settings; and LUCID-21-302, a new chemical entity targeting multiple sclerosis. The CEO announced that unbuzzd™'s RTD formulation is expected in Q1 2025, following successful clinical trials.
Quantum BioPharma (NASDAQ: QNTM) announced that its licensee Celly Nutrition , developer of unbuzzd™ (a beverage that accelerates alcohol metabolism), has engaged a leading New York Investment Bank to raise up to $10 million USD and explore an IPO on a major US exchange.
Quantum BioPharma owns 25.71% of Celly Nutrition and receives 7% royalty on unbuzzd™ sales until reaching $250 million, after which it drops to 3% in perpetuity. The company retains full rights to develop similar products for pharmaceutical and medical uses.
The Letter of Engagement signed on February 4, 2025, covers financial advisory services for a potential Go-Public Transaction and managing the proposed public offering. Celly Nutrition plans to use the capital to accelerate marketing, retail, and direct-to-consumer sales development of unbuzzd™.
Quantum BioPharma (NASDAQ: QNTM) has announced successful results from a double-blind, randomized, placebo-controlled clinical trial for unbuzzd™, their dietary supplement designed to combat alcohol intoxication effects. The study demonstrated that unbuzzd™ accelerated blood alcohol concentration (BAC) reduction by over 40% within 30 minutes compared to placebo.
Key findings showed statistically significant improvements in:
- Alcohol metabolism acceleration
- Enhanced alertness within 30 minutes
- Stabilized heart rate and blood pressure
- Reduced perceived impairment and mental fatigue
- 67% reduction in hangover headache severity
The trial included participants aged 21-43 of both genders, with weights ranging from 119-232 pounds. The product showed no adverse effects and was well-tolerated by all participants. unbuzzd™ is currently licensed to Celly Nutrition Corp. and available for purchase.
Quantum BioPharma (NASDAQ:QNTM) announced upcoming court proceedings against former CEO Dr. Raza Bokhari on January 24, 2025, seeking to declare him a vexatious litigant. The company has previously won multiple legal battles against Bokhari, who was terminated for cause in July 2021, resulting in approximately $3 million in awards in favor of Quantum BioPharma.
An arbitrator dismissed Bokhari's wrongful dismissal claim and awarded the company CDN$2.81 million plus interest. Additional court costs awarded include $175,000 from Justice Conway and $5,000 from the Court of Appeal. The U.S. District Court granted judgment in favor of Quantum BioPharma, including various monetary awards with interest rates ranging from 4% to 6%. Bokhari has appealed this judgment and provided a supersedeas bond for USD $2,882,441.48 pending the United States Court of Appeals decision.
FAQ
What is the current stock price of Quantum BioPharma (QNTM)?
What is the market cap of Quantum BioPharma (QNTM)?
